Literature DB >> 11308054

Physiology of cytokine pathways in rheumatoid arthritis.

W P Arend1.   

Abstract

This review has summarized the physiology of some cytokine pathways in RA, emphasizing the redundant and synergistic nature of this network. However, it is important to understand that this system is self-regulating through the action of anti-inflammatory cytokines, opposing cytokines, cytokine receptor antagonists, and possibly naturally occurring antibodies to cytokines (Figure 1). Disease results when an imbalance in the cytokine network develops, either from excess production of pro-inflammatory cytokines or from inadequate presence of natural anti-inflammatory mechanisms. The current therapeutic approaches to RA that are aimed at restoring this balance include the use of monoclonal antibodies to TNFalpha, soluble TNFalpha receptors, and IL-1Ra. Other therapeutic agents that interfere with the cytokine network are in various stages of preclinical and clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11308054     DOI: 10.1002/1529-0131(200102)45:1<101::AID-ANR90>3.0.CO;2-7

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  49 in total

1.  Protective effect of eotaxin-2 inhibition in adjuvant-induced arthritis.

Authors:  J N Ablin; M Entin-Meer; V Aloush; S Oren; O Elkayam; J George; I Barshack
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 2.  Metalloproteinases, inflammation, and rheumatoid arthritis.

Authors:  F F Mohammed; D S Smookler; R Khokha
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

3.  K/B×N serum transfer arthritis is delayed and less severe in leukaemia inhibitory factor (LIF)-deficient mice.

Authors:  A Upadhyay; D Senyschyn; L Santos; R Gu; G J Carroll; J A Jazayeri
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

4.  Treg cell numbers and function in patients with antibiotic-refractory or antibiotic-responsive Lyme arthritis.

Authors:  Shiqian Shen; Junghee J Shin; Klemen Strle; Gail McHugh; Xin Li; Lisa J Glickstein; Elise E Drouin; Allen C Steere
Journal:  Arthritis Rheum       Date:  2010-07

5.  Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy.

Authors:  Tetsuya Amano; Satoshi Yamasaki; Naoko Yagishita; Kaneyuki Tsuchimochi; Hiroshi Shin; Ko-ichi Kawahara; Satoko Aratani; Hidetoshi Fujita; Lei Zhang; Rie Ikeda; Ryoji Fujii; Naoki Miura; Setsuro Komiya; Kusuki Nishioka; Ikuro Maruyama; Akiyoshi Fukamizu; Toshihiro Nakajima
Journal:  Genes Dev       Date:  2003-09-15       Impact factor: 11.361

6.  Serum resistin levels in patients with rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis.

Authors:  Qing Huang; Sha-Sha Tao; Yu-Jing Zhang; Chao Zhang; Lian-Ju Li; Wei Zhao; Meng-Qin Zhao; Peng Li; Hai-Feng Pan; Chen Mao; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2015-05-03       Impact factor: 2.980

7.  Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model.

Authors:  Kenneth A Howard; Søren R Paludan; Mark A Behlke; Flemming Besenbacher; Bent Deleuran; Jørgen Kjems
Journal:  Mol Ther       Date:  2008-09-30       Impact factor: 11.454

8.  Anticytokine therapy for periodontal diseases: Where are we now?

Authors:  Yogesh Prakash Waykole; S S Doiphode; P S Rakhewar; Maya Mhaske
Journal:  J Indian Soc Periodontol       Date:  2009-05

9.  Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice.

Authors:  Hiroshi Hata; Noriko Sakaguchi; Hiroyuki Yoshitomi; Yoichiroh Iwakura; Kenji Sekikawa; Yoshiaki Azuma; Chieko Kanai; Eiko Moriizumi; Takashi Nomura; Takashi Nakamura; Shimon Sakaguchi
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial.

Authors:  David R Mandel; Katy Eichas; Judith Holmes
Journal:  BMC Complement Altern Med       Date:  2010-01-12       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.